The week’s biggest insider buy was not a buy, and the clue is that the number is round James I. Healy · Rapport Therapeutics · Form 4, 30 October
- Who
- James I. Healy, a director of Rapport Therapeutics, reporting through four investment vehicles. He disclaims beneficial ownership except to the extent of any pecuniary interest.
- What he did
- Acquired 969,480 shares on 28 October 2026 at $21.00 flat, for $20,359,080. Split: Sofinnova Venture Partners XI, L.P. 952,380; SummitTX Apex SP – Healthcare 3 6,395; SummitTX Alpha SP – Healthcare 3 3,772; SummitTX Pinnacle Master, L.P. – Healthcare 3 6,933. Reported holdings after: 2,873,888. No Rule 10b5-1 plan cited.
- The document
- Form 4 filed 30 October 2026 at 19:32 ET. Context from Rapport’s pricing release of 28 October and its closing release of 2 November.
Consensus read
A sitting director put $20.4m of money behind a clinical-stage biotech the same week its shares fell hard. Insiders buy for one reason and sell for many; a purchase this size, by someone who sees the data, is the strongest form of the signal. Every wire that covered it — MarketBeat, Investing.com, Kalkine — filed it as “director Healy buys $20.3m in shares.”
That is a fair reading of what a Form 4 “P” code normally means, and it is not stupid: fund managers do decline allocations in companies they have lost faith in.
Contrarian read
This is a venture fund taking a pre-arranged allocation in a discounted financing, at a price no outside buyer could get, on the day the financing was announced. It carries roughly the signal content of an underwriter’s book — which is to say, almost none.
The money is also not his. It is Sofinnova XI’s and three SummitTX vehicles’; Healy’s own exposure is a general-partner and personal-LP slice of that, plausibly low single-digit millions, and the Form 4 says so in the disclaimer that the headlines dropped.
Evidence that discriminates
- The price is flat at $21.00 with no weighted-average range. Open-market accumulation of 969,480 shares in one session produces a range and a footnote of price steps. One price means one negotiated transaction. This is the single fact that separates the two readings, because an open-market buy of this size essentially cannot look like this.
- $21.00 is exactly Rapport’s announced offering price that day, and it was about 24% below the previous close. The shares fell 22% on the news. A conviction buyer pays the market; an allocation holder pays the book. He paid the book.
- 952,380 × $21.00 = $19,999,980. A round dollar figure out of a non-round share count is the signature of a dollar-denominated allocation. Open-market buyers fill round share counts, not round dollar totals.
- The vehicles are funds, and the Form 4 disclaims pecuniary interest beyond his share. The $20.4m headline uses the gross transaction as a proxy for one man’s conviction. The denominator is wrong by roughly an order of magnitude.
Inference, labelled: that Healy’s personal money in this is low single-digit millions is my estimate from ordinary GP-commitment economics, not a disclosed figure. The filing discloses no dollar amount attributable to him.
What would falsify me
A Form 4 amendment or a 13D/G showing any material part of the 969,480 shares held directly by Healy rather than by the funds; or a footnote showing the shares were bought in the open market at varying prices across the session; or disclosure of a personal commitment by Healy of a size comparable to the headline. Any of those restores the consensus reading, and I would say so.
Pattern vs his own historyRapport priced $175m of stock plus up to $25m of pre-funded warrants and $150m of 2.25% convertible notes due 2032 (initial conversion price about $26.775, a 27.5% premium), alongside roughly $30.0m of stock sold at $21.00 to an unnamed investor in a concurrent private placement. The offerings closed on 2 November with the underwriters’ options fully exercised, netting about $411m. The raise followed a Phase 2a bipolar mania readout a week earlier in which RAP-219 beat placebo by 3.1 points with more agitation — a result good enough to finance on and not good enough to finance at the old price. Whether Healy’s shares sat in the registered offering or the private placement is not determinable from the reachable sources, and the argument does not turn on it.